Klor-con/ef Tablet, Effervescent
NDC Package 0245-5326-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Klor-con/ef (potassium bicarbonate) tablets is for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. This formulation utilizes a tablet, effervescent delivery system. Marketed by Upsher-smith Laboratories, Inc., this product is identified by NDC 0245-5326.

Identification & Billing

NDC Package Code
0245-5326-01
Package Description
100 POUCH in 1 CARTON / 1 TABLET, EFFERVESCENT in 1 POUCH (0245-5326-89)
Product Code
0245-5326
11-Digit Billing Format
00245532601
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Klor-con/ef
Non-Proprietary Name
Potassium Bicarbonate
Substance Name
Potassium Bicarbonate
Dosage Form
Tablet, Effervescent - A solid dosage form containing mixtures of acids (e.g., citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
POTASSIUM BICARBONATE 978 mg/1
Pharmacologic Class
Usage Information
For the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias).The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

Regulatory & Marketing

Labeler Name
Upsher-smith Laboratories, Inc.
Product Type
Human Prescription Drug
Marketing Category
UNAPPROVED DRUG OTHER - An unapproved drug product in a marketing category that is not reflected on a particular list.
Start Marketing Date
09-01-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0245-5326). Click a package code to view its specific billing and regulatory data.

0245-5326-30
30 POUCH in 1 CARTON / 1 TABLET, EFFERVESCENT in 1 POUCH (0245-5326-89)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0245-5326-01 identifies a specific commercial package of 100 pouch in 1 carton / 1 tablet, effervescent in 1 pouch (0245-5326-89) of Klor-con/ef, a human prescription drug labeled by Upsher-smith Laboratories, Inc.. This tablet, effervescent is formulated for oral use and contains potassium bicarbonate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Upsher-smith Laboratories, Inc. on September 01, 2014. The current certification is valid through December 31, 2026.

How is this Upsher-smith Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00245532601. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0245-5326-01
11-Digit CMS (5-4-2)
00245-5326-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.